Epigenetic alterations in cervical carcinogenesis

Seminars in Cancer Biology

Volumn 19, Issue 3, 2009, Pages 144-152

  Szalmás, Anita ^a   Kónya, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cervical cancer; CpG methylation; Epigenetic silencing; Human papillomavirus; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BIOLOGICAL MARKER; HYDRALAZINE; OSTEONECTIN; PLACENTA PROTEIN 5; RETINOIC ACID RECEPTOR BETA; SYNUCLEIN; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CERVICAL CARCINOGENESIS; DNA REPAIR; DRUG EFFICACY; DRUG TOLERABILITY; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; METHYLATION; NONHUMAN; POU2F3 GENE; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX; UTERINE CERVIX CANCER; VIRUS EXPRESSION; VIRUS REPLICATION;

CELL TRANSFORMATION, VIRAL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; PAPILLOMAVIRIDAE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 63449123166     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.02.011     Document Type: Review

References (97)

1. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
2. Steenbergen R.D., de Wilde J., Wilting S.M., Brink A.A., Snijders P.J., and Meijer C.J. HPV-mediated transformation of the anogenital tract. J Clin Virol 32 Suppl. 1 (2005) S25-S33
3. Henken F.E., Wilting S.M., Overmeer R.M., van Rietschoten J.G., Nygren A.O., Errami A., et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 97 (2007) 1457-1464
4. Berger S.L. The complex language of chromatin regulation during transcription. Nature 447 (2007) 407-412
5. Klose R.J., and Bird A.P. Genomic DNA methylation. The mark and its mediators. Trends Biochem Sci 31 (2006) 89-97
6. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
7. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148-1159
8. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24 (2000) 132-138
9. van Hamont D., Bekkers R.L., Massuger L.F., and Melchers W.J. Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Rev Med Virol 18 (2008) 117-132
10. Burnett T.S., and Sleeman J.P. Uneven distribution of methylation sites within the human papillomavirus la genome: possible relevance to viral gene expression. Nucleic Acids Res 12 (1984) 8847-8860
11. List H.J., Patzel V., Zeidler U., Schopen A., Ruhl G., Stollwerk J., et al. Methylation sensitivity of the enhancer from the human papillomavirus type 16. J Biol Chem 269 (1994) 11902-11911
12. Rosl F., Arab A., Klevenz B., and zur H.H. The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol 74 Pt 5 (1993) 791-801
13. Thain A., Jenkins O., Clarke A.R., and Gaston K. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J Virol 70 (1996) 7233-7235
14. Choo K.B., Liew L.N., Liew S.J., and Cheng W.T. Hypermethylation of the human papillomavirus transgenome in transgenic mice. Proc Natl Sci Counc Repub China B 17 (1993) 159-163
15. Tan S.H., Bartsch D., Schwarz E., and Bernard H.U. Nuclear matrix attachment regions of human papillomavirus type 16 point toward conservation of these genomic elements in all genital papillomaviruses. J Virol 72 (1998) 3610-3622
16. Stunkel W., and Bernard H.U. The chromatin structure of the long control region of human papillomavirus type 16 represses viral oncoprotein expression. J Virol 73 (1999) 1918-1930
17. Burgers W.A., Blanchon L., Pradhan S., de Launoit Y., Kouzarides T., and Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 26 (2007) 1650-1655
18. Longworth M.S., Wilson R., and Laimins L.A. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J 24 (2005) 1821-1830
19. Zhang B., Laribee R.N., Klemsz M.J., and Roman A. Human papillomavirus type 16 E7 protein increases acetylation of histone H3 in human foreskin keratinocytes. Virology 329 (2004) 189-198
20. Longworth M.S., and Laimins L.A. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 78 (2004) 3533-3541
21. Van Tine B.A., Kappes J.C., Banerjee N.S., Knops J., Lai L., Steenbergen R.D., et al. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol 78 (2004) 11172-11186
22. Kalantari M., Lee D., Calleja-Macias I.E., Lambert P.F., and Bernard H.U. Effects of cellular differentiation, chromosomal integration and 5-aza-2′-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology 374 (2008) 292-303
23. Badal V., Chuang L.S., Tan E.H., Badal S., Villa L.L., Wheeler C.M., et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 77 (2003) 6227-6234
24. Kalantari M., Calleja-Macias I.E., Tewari D., Hagmar B., Lie K., Barrera-Saldana H.A., et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 78 (2004) 12762-12772
25. Rajeevan M.S., Swan D.C., Duncan K., Lee D.R., Limor J.R., and Unger E.R. Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. J Virol Methods 138 (2006) 170-176
26. Bhattacharjee B., and Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 354 (2006) 280-285
27. Badal S., Badal V., Calleja-Macias I.E., Kalantari M., Chuang L.S., Li B.F., et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 324 (2004) 483-492
28. Turan T., Kalantari M., Calleja-Macias I.E., Cubie H.A., Cuschieri K., Villa L.L., et al. Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?. Virology 349 (2006) 175-183
29. De Castro A.J., Gockel-Krzikalla E., and Rosl F. Retinoic acid receptor beta silences human papillomavirus-18 oncogene expression by induction of de novo methylation and heterochromatinization of the viral control region. J Biol Chem 282 (2007) 28520-28529
30. Meyers C., Frattini M.G., Hudson J.B., and Laimins L.A. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257 (1992) 971-973
31. Stanley M.A., Browne H.M., Appleby M., and Minson A.C. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer 43 (1989) 672-676
32. Wooldridge T.R., and Laimins L.A. Regulation of human papillomavirus type 31 gene expression during the differentiation-dependent life cycle through histone modifications and transcription factor binding. Virology 374 (2008) 371-380
33. Kim K., Garner-Hamrick P.A., Fisher C., Lee D., and Lambert P.F. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 77 (2003) 12450-12459
34. Woodman C.B., Collins S., Rollason T.P., Winter H., Bailey A., Yates M., et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 361 (2003) 40-43
35. Kalantari M., Villa L.L., Calleja-Macias I.E., and Bernard H.U. Human papillomavirus-16 and -18 in penile carcinomas: DNA methylation, chromosomal recombination and genomic variation. Int J Cancer 123 (2008) 1832-1840
36. Balderas-Loaeza A., Anaya-Saavedra G., Ramirez-Amador V.A., Guido-Jimenez M.C., Kalantari M., Calleja-Macias I.E., et al. Human papillomavirus-16 DNA methylation patterns support a causal association of the virus with oral squamous cell carcinomas. Int J Cancer 120 (2007) 2165-2169
37. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., and Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10 (2001) 687-692
38. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
39. Kim Y.I., Giuliano A., Hatch K.D., Schneider A., Nour M.A., Dallal G.E., et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 74 (1994) 893-899
40. de Capoa A., Musolino A., Della R.S., Caiafa P., Mariani L., Del Nonno F., et al. DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncol Rep 10 (2003) 545-549
41. Douc-Rasy S., Barrois M., Fogel S., Ahomadegbe J.C., Stehelin D., Coll J., et al. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene 12 (1996) 423-430
42. Szalmas A., Banati F., Koroknai A., Laszlo B., Feher E., Salamon D., et al. Lineage-specific silencing of human IL-10 gene expression by promoter methylation in cervical cancer cells. Eur J Cancer 44 (2008) 1030-1038
43. Piyathilake C.J., Celedonio J.E., Macaluso M., Bell W.C., Azrad M., and Grizzle W.E. Mandatory fortification with folic acid in the United States is associated with increased expression of DNA methyltransferase-1 in the cervix. Nutrition 24 (2008) 94-99
44. Goodman M.T., McDuffie K., Hernandez B., Wilkens L.R., Bertram C.C., Killeen J., et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 10 (2001) 1275-1280
45. Zoodsma M., Nolte I.M., Schipper M., Oosterom E., van der S.G., de Vries E.G., et al. Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet 116 (2005) 247-254
46. Duenas-Gonzalez A., Lizano M., Candelaria M., Cetina L., Arce C., and Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4 (2005) 38
47. Chan T.F., Su T.H., Yeh K.T., Chang J.Y., Lin T.H., Chen J.C., et al. epigenetic and expressional analyses of caveolin-1 gene in cervical cancers. Int J Oncol 23 (2003) 599-604
48. Ivanova T., Petrenko A., Gritsko T., Vinokourova S., Eshilev E., Kobzeva V., et al. Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer 2 (2002) 4
49. Gustafson K.S., Furth E.E., Heitjan D.F., Fansler Z.B., and Clark D.P. DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis. Cancer 102 (2004) 259-268
50. Nuovo G.J., Plaia T.W., Belinsky S.A., Baylin S.B., and Herman J.G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96 (1999) 12754-12759
51. Virmani A.K., Muller C., Rathi A., Zoechbauer-Mueller S., Mathis M., and Gazdar A.F. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7 (2001) 584-589
52. Wong Y.F., Chung T.K., Cheung T.H., Nobori T., Yu A.L., Yu J., et al. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett 136 (1999) 231-235
53. Kim N.R., Lin Z., Kim K.R., Cho H.Y., and Kim I. Epstein-Barr virus and p16INK4A methylation in squamous cell carcinoma and precancerous lesions of the cervix uteri. J Korean Med Sci 20 (2005) 636-642
54. Lin Z., Gao M., Zhang X., Kim Y.S., Lee E.S., Kim H.K., et al. The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol 131 (2005) 364-370
55. Lea J.S., Coleman R., Kurien A., Schorge J.O., Miller D.S., Minna J.D., et al. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 190 (2004) 674-679
56. Ren C.C., Miao X.H., Yang B., Zhao L., Sun R., and Song W.Q. Methylation status of the fragile histidine triad and E-cadherin genes in plasma of cervical cancer patients. Int J Gynecol Cancer 16 (2006) 1862-1867
57. Choi C.H., Lee K.M., Choi J.J., Kim T.J., Kim W.Y., Lee J.W., et al. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett 255 (2007) 26-33
58. Wu Q., Shi H., Suo Z., and Nesland J.M. 5′-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas. Ultrastruct Pathol 27 (2003) 417-422
59. Kitkumthorn N., Yanatatsanajit P., Kiatpongsan S., Phokaew C., Triratanachat S., Trivijitsilp P., et al. Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. BMC Cancer 6 (2006) 55
60. Dong S.M., Kim H.S., Rha S.H., and Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7 (2001) 1982-1986
61. Kang S., Kim J.W., Kang G.H., Lee S., Park N.H., Song Y.S., et al. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 118 (2006) 2168-2171
62. Narayan G., Arias-Pulido H., Koul S., Vargas H., Zhang F.F., Villella J., et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2 (2003) 24
63. Shivapurkar N., Sherman M.E., Stastny V., Echebiri C., Rader J.S., Nayar R., et al. Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol 107 (2007) 549-553
64. Wisman G.B., Nijhuis E.R., Hoque M.O., Reesink-Peters N., Koning A.J., Volders H.H., et al. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 119 (2006) 1908-1914
65. Yang H.J., Liu V.W., Wang Y., Chan K.Y., Tsang P.C., Khoo U.S., et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 93 (2004) 435-440
66. Kuzmin I., Liu L., Dammann R., Geil L., Stanbridge E.J., Wilczynski S.P., et al. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 63 (2003) 1888-1893
67. Cohen Y., Singer G., Lavie O., Dong S.M., Beller U., and Sidransky D. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 9 (2003) 2981-2984
68. Kang S., Kim H.S., Seo S.S., Park S.Y., Sidransky D., and Dong S.M. Inverse correlation between RASSF1A hypermethylation. KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol 105 (2007) 662-666
69. Lai H.C., Lin Y.W., Chang C.C., Wang H.C., Chu T.W., Yu M.H., et al. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol 104 (2007) 629-635
70. Yang H.J., Liu V.W., Wang Y., Tsang P.C., and Ngan H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6 (2006) 212
71. Kang S., Kim J.W., Kang G.H., Park N.H., Song Y.S., Kang S.B., et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 96 (2005) 173-180
72. Narayan G., Arias-Pulido H., Nandula S.V., Basso K., Sugirtharaj D.D., Vargas H., et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64 (2004) 2994-2997
73. Widschwendter A., Gattringer C., Ivarsson L., Fiegl H., Schneitter A., Ramoni A., et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 10 (2004) 3396-3400
74. Cheung T.H., Lo K.W., Yim S.F., Chan L.K., Heung M.S., Chan C.S., et al. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 93 (2004) 621-627
75. Sova P., Feng Q., Geiss G., Wood T., Strauss R., Rudolf V., et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 15 (2006) 114-123
76. Zhang Z., Joh K., Yatsuki H., Zhao W., Soejima H., Higashimoto K., et al. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells. Cancer Lett 247 (2007) 318-327
77. Zhang Z., Huettner P.C., Nguyen L., Bidder M., Funk M.C., Li J., et al. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 25 (2006) 5436-5445
78. Lai H.C., Lin Y.W., Huang T.H., Yan P., Huang R.L., Wang H.C., et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 123 (2008) 161-167
79. Widschwendter A., Ivarsson L., Blassnig A., Muller H.M., Fiegl H., Wiedemair A., et al. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109 (2004) 163-166
80. Li J., Zhang Z., Bidder M., Funk M.C., Nguyen L., Goodfellow P.J., et al. IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol 96 (2005) 150-158
81. Narayan G., Goparaju C., Arias-Pulido H., Kaufmann A.M., Schneider A., Durst M., et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer 5 (2006) 16
82. Jeong D.H., Youm M.Y., Kim Y.N., Lee K.B., Sung M.S., Yoon H.K., et al. Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 16 (2006) 1234-1240
83. Ivanova T., Vinokurova S., Petrenko A., Eshilev E., Solovyova N., Kisseljov F., et al. Frequent hypermethylation of 5′ flanking region of TIMP-2 gene in cervical cancer. Int J Cancer 108 (2004) 882-886
84. Kahn S.L., Ronnett B.M., Gravitt P.E., and Gustafson K.S. Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests. Cancer 114 (2008) 57-64
85. Mulero-Navarro S., and Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68 (2008) 1-11
86. Feng Q., Balasubramanian A., Hawes S.E., Toure P., Sow P.S., Dem A., et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 97 (2005) 273-282
87. Muller H.M., Widschwendter A., Fiegl H., Goebel G., Wiedemair A., Muller-Holzner E., et al. A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett 209 (2004) 231-236
88. Feng Q., Hawes S.E., Stern J.E., Dem A., Sow P.S., Dembele B., et al. Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol Biomarkers Prev 16 (2007) 1178-1184
89. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Mariscal I., Chavez A., et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 9 (2003) 1596-1603
90. Song Y., and Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol (2008)
91. Zambrano P., Segura-Pacheco B., Perez-Cardenas E., Cetina L., Revilla-Vazquez A., Taja-Chayeb L., et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5 (2005) 44
92. Cruz-Hernandez E., Perez-Cardenas E., Contreras-Paredes A., Cantu D., Mohar A., Lizano M., et al. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 4 (2007) 18
93. Chen J., Ghazawi F.M., Bakkar W., and Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 5 (2006) 71
94. Sami S., Hoti N., Xu H.M., Shen Z., and Huang X. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 144 (2008) 357-362
95. Chavez-Blanco A., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Cetina L., Candelaria M., et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 4 (2005) 22
96. Chavez-Blanco A., Perez-Plasencia C., Perez-Cardenas E., Carrasco-Legleu C., Rangel-Lopez E., Segura-Pacheco B., et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6 (2006) 2
97. You J.S., Kang J.K., Lee E.K., Lee J.C., Lee S.H., Jeon Y.J., et al. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 27 (2008) 1376-1386